Skip to main content
. 2021 Apr 15;13(8):1907. doi: 10.3390/cancers13081907

Figure 1.

Figure 1

Four-year progression-free survival (PFS) of 102 children with Burkitt leukemia or stage IV Burkitt lymphoma according to minimal residual disease before the second course of Berlin-Frankfurt-Muenster (BFM)-type chemotherapy as measured by long-distance PCR for MYC-IGH or patient-specific IG rearrangements (from Mussolin et al. [38]).